Biocon India
Exclusive | Kiran Majumdar Shaw on how Biocon hopes to beat COVID-19
Kiran Mazumdar Shaw, Biocon’s executive chairperson, is delighted that Biocon’s COVID-19 drug Itolizumab is DCGI-approved
Future jobs will be different: Shaw
It is important that the country focused on affordability to ensure that technology is accessible to all.
1 of 1